The effect of cyclooxygenase-2 inhibitors on bone mineral density: Results from the Canadian Multicentre Osteoporosis Study

Osteoporosis International

Volumn 17, Issue 9, 2006, Pages 1410-1419

  Richards, J B ^a   Joseph, L ^a   Schwartzman, K ^a   Kreiger, N ^b   Tenenhouse, A ^a   Goltzman, D ^a,c  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

Bone mineral density; Cyclooxygenase 2 inhibitors; Inflammation; Osteoporosis

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; ESTROGEN; PARACETAMOL; ROFECOXIB;

AGE DISTRIBUTION; AGED; ARTICLE; BONE DENSITY; BONE FRAGILITY; CANADA; CONFIDENCE INTERVAL; CONTROLLED STUDY; DATA ANALYSIS; DOSE RESPONSE; DRUG EFFECT; ESTROGEN THERAPY; FEMALE; FRACTURE; HIP; HUMAN; MAJOR CLINICAL STUDY; MALE; OSTEOPOROSIS; OUTCOME ASSESSMENT; POSTMENOPAUSE; PRIORITY JOURNAL; RISK; SEX ROLE; STRUCTURED INTERVIEW;

ACETAMINOPHEN; ADULT; AGED; BODY MASS INDEX; BONE DENSITY; CYCLOOXYGENASE 2 INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTROGEN REPLACEMENT THERAPY; FEMALE; FEMUR; HIP JOINT; HUMANS; LUMBAR VERTEBRAE; MALE; MIDDLE AGED; OSTEOARTHRITIS; OSTEOPOROSIS; PROSPECTIVE STUDIES; SEX FACTORS;

EID: 33746387887     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-006-0142-x     Document Type: Article

References (39)

1. Raisz LG (1999) Prostaglandins and bone: physiology and pathophysiology. Osteoarthr Cartil 7(4):419-421
2. Pfeilschifter J, Koditz R, Pfohl M, Schatz H (2002) Changes in proinflammatory cytokine activity after menopause. Endocr Rev 23(1):90-119
3. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Konstam MA, Baron JA, the Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators (2005) Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352(11):1092-1102
4. Solomon SD, McMurray JJV, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M, the Adenoma Prevention with Celecoxib (APC) Study Investigators (2005) Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352(11):1071-1080
5. Thorsen K, Kristoffersson AO, Lerner UH, Lorentzon RP (1996) In situ microdialysis in bone tissue. Stimulation of prostaglandin E(2) release by weight-bearing mechanical loading. J Clin Invest 98(11):2446-2449
6. Zaman G, Suswillo RFL, Cheng MZ, Tavares IA, Lanyon LE (1997) Early responses to dynamic strain change and prostaglandins in bone-derived cells in culture. J Bone Miner Res 12(5):769-777
7. Bakker AD, Klein-Nulend J, Burger EH (2003) Mechanotransduction in bone cells proceeds via activation of COX-2, but not COX-1. Biochem Biophys Res Commun 305 (3):677-683
8. Klein-Nulend J, Burger EH, Semeins CM, Raisz LG, Pilbeam CC (1997) Pulsating fluid flow stimulates prostaglandin release and inducible prostaglandin G/H synthase mRNA expression in primary mouse bone cells. J Bone Miner Res 12(1):45-51
9. Forwood MR (1996) Inducible cyclo-oxygenase (COX-2) mediates the induction of bone formation by mechanical loading in vivo. J Bone Miner Res 11(11):1688-1693
10. Okada Y, Lorenzo JA, Freeman AM, Tomita M, Morham SG, Raisz LG, Pilbeam CC (2000) Prostaglandin G/H synthase-2 is required for maximal formation of osteoclast-like cells in culture. J Clin Invest 105(6):823-832
11. Min YK, Rao Y, Okada Y, Raisz LG, Pilbeam CC (1998) Regulation of prostaglandin G/H synthase-2 expression by interleukin-1 in human osteoblast-like cells. J Bone Miner Res 13(7):1066-1075
12. Kawaguchi H, Pilbeam CC, Vargas SJ, Morse EE, Lorenzo JA, Raisz LG (1995) Ovariectomy enhances and estrogen replacement inhibits the activity of bone-marrow factors that stimulate prostaglandin production in cultured mouse calvariae. J Clin Invest 96(1):539-548
13. Hardy MM, Seibert K, Manning PT, Currie MG, Woerner BM, Edwards D, Koki A, Tripp CS (2002) Cyclooxygenase 2-dependent prostaglandin E-2 modulates cartilage proteoglycan degradation in human osteoarthritis explants. Arthritis Rheum 46(7):1789-1803
14. Cenci S, Weitzmann MN, Roggia C, Namba N, Novack D, Woodring J, Pacifici R (2000) Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-alpha. J Clin Invest 106(10):1229-1237
15. Hofbauer LC, Lacey DL, Dunstan CR, Spelsberg TC, Riggs BL, Khosla S (1999) Interleukin-1 beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone 25(3):255-259
16. Bauer DC, Orwoll ES, Fox KM, Vogt TM, Lane NE, Hochberg MC, Stone K, Nevitt MC (1996) Aspirin and NSAID use in older women: effect on bone mineral density and fracture risk. J Bone Miner Res 11(1):29-35
17. Morton DJ, Barrett-Connor EL, Schneider DL (1998) Nonsteroidal anti-inflammatory drugs and bone mineral density in older women: the Rancho Bemardo study. J Bone Miner Res 13(12):1924-1931
18. Carbone LD, Tylavsky FA, Cauley JA, Harris TB, Lang TF, Bauer DC, Barrow KD, Kritchevsky SB (2003) Association between bone mineral density and the use of nonsteroidal anti-inflammatory drugs and aspirin: impact of cyclooxygenase selectivity. J Bone Miner Res 18(10):1795-1802
19. Lane NE, Bauer DC, Nevitt MC, Pressman AR, Cummings SR (1997) Aspirin and nonsteroidal antiinflammatory drug use in elderly women: effects on a marker of bone resorption. J Rheumatol 24(6):1132-1136
20. Vane JR, Botting RM (2003) The mechanism of action of aspirin. Thromb Res 110(5-6):255-258
21. Kreiger N, Tenenhouse A, Joseph L, Mackenzie T, Poliquin S, Brown JP, Prior JC, Rittmaster RS (1999) Research notes: the Canadian Multicentre Ssteoporosis Study (CaMos): background, rationale, methods. Can J Aging 18(3):376-387
22. Geba GP, Weaver AL, Polis AB, Dixon ME, Schnitzer TJ, for the VACT Group (2002) Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee: a randomized trial. JAMA 287(1):64-71
23. Genant HK, Grampp S, Gluer CC, Faulkner KG, Jergas M, Engelke K, Hagiwara S, Vankuijk C (1994) Universal standardization for dual X-ray absorptiometry - patient and phantom cross-calibration results. J Bone Miner Res 9(10):1503-1514
24. Pearson J, Dequeker J, Henley M, Bright J, Reeve J, Kalender W, Lavaljeantet AM, Ruegsegger P, Felsenberg D, Adams J, Birkenhager JC, Braillon P, Curiel MD, Fischer M, Galan F, Geusens P, Hyldstrup L, Jaeger P, Jonson R, Kalefezras J, Kotzki P, Kroger H, Vanlingen A, Nilsson S, Osteaux M, Cano RP, Reid DM, Reiners C, Ribot C, Schneider P, Slosman DO, Wittenberg G (1995) European semi-anthropomorphic spine phantom for the calibration of bone densitometers: assessment of precision, stability and accuracy. The European Quantitation of Osteoporosis Study Group. Osteoporos Int 5(3):174-184
25. Jamal SA, Browner WS, Bauer DC, Cummings SR (1998) Intermittent use of nitrates increases bone mineral density: the study of osteoporotic fractures. J Bone Miner Res 13(11):1755-1759
26. Cryer B, Feldman M (1998) Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med 104(5):413-421
27. Shumaker SA, Legault C, Kuller L, Rapp SR, Thal L, Lane DS, Fillit H, Stefanick ML, Hendrix SL, Lewis CE, Masaki K, Coker LH, for the Women's Health Initiative Memory Study (2004) Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: women's health initiative memory study. JAMA 291(24):2947-2958
28. Writing Group for the Women's Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women's health initiative randomized controlled trial. JAMA 288(3):321-333
29. Brunner RL, Gass M, Aragaki A, Hays J, Granek I, Woods N, Mason E, Brzyski R, Ockene J, Assaf A, LaCroix A, Matthews K, Wallace R, for the Women's Health Initiative Investigators (2005) Effects of conjugated equine estrogen on health-related quality of life in postmenopausal women with hysterectomy: results from the women's health initiative randomized clinical trial. Arch Intern Med 165(17):1976-1986
30. Roth GJ, Stanford N, Majerus PW (1975) Acetylation of prostaglandin synthase by aspirin. Proc Natl Acad Sci U S A 72(8):3073-3076
31. Stewart A, Black AJ (2000) Bone mineral density in osteoarthritis. Curr Opin Rheumatol 12(5):464-467
32. Hochberg MC, Altman RD, Brandt KD, Clark BM, Dieppe PA, Griffin MR, Moskowitz RW, Schnitzer TJ (1995) Guidelines for the medical-management of osteoarthritis. 1. Osteoarthritis of the hip. Arthritis Rheum 38(11):1535-1540
33. Bertin P, Keddad K, Jolivet-Landreau I (2004) Acetaminophen as symptomatic treatment of pain from osteoarthritis. Joint Bone Spine 71(4):266-274
34. Cauley JA, Fullman RL, Stone KL, Zmuda JM, Bauer DC, Barrett-Connor E, Ensrud K, Lau EM, Orwoll ES (2005) Factors associated with the lumbar spine and proximal femur bone mineral density in older men. Osteoporos Int 16(12):1525-1537
35. Meunier PJ, Slosman DO, Delmas PD, Sebert JL, Brandi ML, Albanese C, Lorenc R, Pors-Nielsen S, De Vernejoul MC, Roces A, Reginster JY (2002) Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis - a 2-year randomized placebo controlled trial. J Clin Endocrinol Metab 87(5):2060-2066
36. Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW, Dequeker J, Favus M, Seeman E, Recker RR, Capizzi T, Santora AC, Lombardi A, Shah RV, Hirsch LJ, Karpf DB, The Alendronate Phase III Osteoporosis Treatment Study Group (1995) Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 333(22):1437-1444
37. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH III, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD, for the Vertebral Efficacy with Risedronate Therapy Study Group (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA 282(14):1344-1352
38. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR, for the Multiple Outcomes of Raloxifene Evaluation Investigators (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 282(7):637-645
39. Cummings SR (1993) Bone density at various sites for prediction of hip fractures. Lancet 341:72-75